4
ALL4
SpineTheraYear
4
ALL1
20241
20232
2022DEALS // DEV.
4
ALL2
Deals2
DevelopmentsCountry
4
ALL4
U.S.A4
ALL1
Department of Defense1
Mayo Clinic2
Not ApplicableTherapeutic Area
4
ALL2
Musculoskeletal1
Neurology1
Psychiatry/PsychologyStudy Phase
4
ALL3
Phase I/ Phase II1
UndisclosedDeal Type
2
ALL1
Collaboration1
FundingProduct Type
4
ALL3
Small molecule1
UndisclosedDosage Form
3
ALL1
Epidural Injection1
Injectable/Injection1
Injection, Extended ReleaseLead Product
4
ALL3
Dexamethasone1
UndisclosedTarget
1
ALL1
Glucocorticoid receptorLead Product(s) : Undisclosed
Therapeutic Area : Psychiatry/Psychology
Study Phase : Undisclosed
Sponsor : Mayo Clinic
Deal Size : Undisclosed
Deal Type : Collaboration
SpineThera Collaborates with Mayo Clinic for Substance Abuse Disorder Solutions
Details : The collaboration aims to develop long-acting injectable drugs to improve treatment outcomes for individuals with substance abuse disorders using it’s novel, long-acting injectable technology.
Brand Name : Undisclosed
Molecule Type : Undisclosed
Upfront Cash : Undisclosed
June 17, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Undisclosed
Sponsor : Mayo Clinic
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Dexamethasone
Therapeutic Area : Musculoskeletal
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : SX600 (dexamethasone) is a novel formulation of extended-release microspheres designed for transforaminal epidural injection in the management of sciatica pain.
Brand Name : SX600
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 06, 2023
Lead Product(s) : Dexamethasone
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Dexamethasone
Therapeutic Area : Neurology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : SX600, is novel formulation of dexamethasone acetate microspheres for micro-suspension injection, was designed as a targeted, extended-release corticosteroid with the potential to demonstrate a substantially improved profile relative to radicular leg pai...
Brand Name : SX600
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 07, 2022
Lead Product(s) : Dexamethasone
Therapeutic Area : Neurology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Dexamethasone
Therapeutic Area : Musculoskeletal
Study Phase : Phase I/ Phase II
Sponsor : Department of Defense
Deal Size : $5.0 million
Deal Type : Funding
SpineThera Awarded $5 Million Grant from Department of Defense
Details : The scope of work supported by this grant award includes nonclinical toxicity testing of SX600 and manufacturing process development and scale-up activities. Together, these activities will position SX600 for future Phase 3 clinical trials.
Brand Name : SX600
Molecule Type : Small molecule
Upfront Cash : Undisclosed
April 26, 2022
Lead Product(s) : Dexamethasone
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase I/ Phase II
Sponsor : Department of Defense
Deal Size : $5.0 million
Deal Type : Funding
LOOKING FOR A SUPPLIER?